Gilead Sciences has officially launched construction on its new state-of-the-art Pharmaceutical Development and Manufacturing (PDM) Technical Development Center (NTDC) at its Foster City, California headquarters. The groundbreaking, held on September 3, 2025, reflects the company’s expanded investment in biologics, AI-driven drug development, and American manufacturing.
The NTDC is a key component of Gilead’s long-term strategy to advance innovation across therapeutic areas such as oncology, virology, and inflammation. The project is part of the company’s previously announced $32 billion commitment to U.S. innovation through 2030, an initiative expected to produce over $43 billion in economic value and expand workforce opportunities nationwide.
“This new facility is part of our vision for delivering next-generation therapies and a cornerstone of Gilead's $32 billion investment commitment in the United States,” said Daniel O'Day, chairman and CEO of Gilead Sciences. “We have multiple construction projects under way, all of which will generate thousands of American jobs and help to drive U.S. leadership in global biopharma innovation.”
The new five-story, 180,000-square-foot NTDC facility will be designed to enhance collaboration across manufacturing and technical development teams. The layout will include:
Once completed, it is expected to be among the most AI-enabled technical development centers in the biopharmaceutical sector.
Although the company has not publicly announced the contractor or total project cost, the facility is poised to become a central hub for biologics development, accelerating preclinical and clinical manufacturing capabilities.
Gilead projects that its broader expansion efforts will result in more than 3,000 direct and indirect jobs across the United States. The company’s plan includes not just the NTDC but additional construction projects tied to research, manufacturing, and development efforts.
California Lt. Gov. Eleni Kounalakis applauded the initiative, stating: “California is proud to be home to Gilead Sciences and its ongoing investment in innovation and jobs right here in Foster City. This new Technical Development Center is more than a milestone for Gilead; it's a win for all who will benefit from its breakthroughs. It demonstrates that when we invest in domestic biomanufacturing, we strengthen supply chains, create thousands of good-paying jobs, and keep America at the forefront of life-saving innovation.”
The NTDC is one of three current construction efforts unfolding at Gilead’s Foster City campus. The two additional projects include:
These initiatives build on more than $15 billion in U.S. investment over the past decade, reinforcing Gilead’s role as a national leader in biopharma research, drug development, and manufacturing.
As work progresses, the Foster City hub is expected to cement Gilead’s position at the forefront of next-generation therapeutic innovation, creating a pipeline that integrates advanced biologics, AI tools, and domestic production infrastructure.
Originally reported by Gilead Sciences in Construction Equipment Guide.
.webp)
